OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Pharmacokinetics and Pharmacodynamics is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Application of different approaches to generate virtual patient populations for the quantitative systems pharmacology model of erythropoiesis	43
Translational physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies	39
Learning pharmacometric covariate model structures with symbolic regression networks	37
Advancing inclusive healthcare through PBPK modelling: predicting the impact of CYP genotypes and enzyme ontogenies on infant exposures of venlafaxine and its active metabolite O-desmethylvenlafaxine	36
Achieving big with small: quantitative clinical pharmacology tools for drug development in pediatric rare diseases	29
Development of PBPK model for intra-articular injection in human: methotrexate solution and rheumatoid arthritis case study	28
Population pharmacokinetic and pharmacodynamic model of propofol externally validated in Korean elderly subjects	22
Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of	21
Model-informed approach to estimate treatment effect in placebo-controlled clinical trials using an artificial intelligence-based propensity weighting methodology to account for non-specific responses	18
Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials	15
Current practices for QSP model assessment: an IQ consortium survey	13
Correction: Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease	12
Translational population target binding model for the anti-FcRn fragment antibody efgartigimod	12
A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration	12
Mixed effect estimation in deep compartment models: Variational methods outperform first-order approximations	12
Semi-mechanistic modeling of resistance development to β-lactam and β-lactamase-inhibitor combinations	12
Training the next generation of pharmacometric modelers: a multisector perspective	12